{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:44:20Z","timestamp":1784691860546,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00198-021-06059-2","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:02:46Z","timestamp":1625634166000},"page":"305-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report"],"prefix":"10.1007","volume":"33","author":[{"given":"S.Y.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-8280","authenticated-orcid":false,"given":"H.Y.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"6059_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","volume":"11","author":"PD Delmas","year":"2008","unstructured":"Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11:325\u2013338","journal-title":"J Clin Densitom"},{"key":"6059_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6059_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"6059_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835","journal-title":"J Bone Miner Res"},{"key":"6059_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.clinthera.2011.10.008","volume":"33","author":"MB Bridgeman","year":"2011","unstructured":"Bridgeman MB, Pathak R (2011) Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther 33:1547\u20131559","journal-title":"Clin Ther"},{"key":"6059_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol 41:129\u2013137","journal-title":"Am J Nephrol"},{"key":"6059_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00520-014-2142-2","volume":"22","author":"B Lechner","year":"2014","unstructured":"Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N, Giotis A, Sheehan P, Tsao M, Bedard G, Chow E (2014) The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer 22:1765\u20131771","journal-title":"Support Care Cancer"},{"key":"6059_CR8","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, Stopeck A, van Poznak C, Dami\u00e3o R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812\u20131821","journal-title":"Eur J Cancer"},{"key":"6059_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00774-018-0928-x","volume":"37","author":"T Asano","year":"2019","unstructured":"Asano T, Shimizu T, Takahashi D, Ota M, Sato D, Hamano H, Hiratsuka S, Takahata M, Iwasaki N (2019) Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. J Bone Miner Metab 37:351\u2013357","journal-title":"J Bone Miner Metab"},{"key":"6059_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2147\/CIA.S180614","volume":"13","author":"K Ishikawa","year":"2018","unstructured":"Ishikawa K, Nagai T, Tsuchiya K, Oshita Y, Kuroda T, Ito H, Tani S, Dodo Y, Toyone T, Inagaki K (2018) High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis. Clin Interv Aging 13:1929\u20131934","journal-title":"Clin Interv Aging"},{"key":"6059_CR11","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831\u20131840","journal-title":"Ther Clin Risk Manag"},{"key":"6059_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","volume":"31","author":"G Tsvetov","year":"2020","unstructured":"Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T (2020) Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 31:655\u2013665","journal-title":"Osteoporos Int"},{"key":"6059_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43:1243\u20131246","journal-title":"Intern Med J"},{"key":"6059_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.11005\/jbm.2019.26.4.213","volume":"26","author":"SY Park","year":"2019","unstructured":"Park SY, Ahn SH, Yoo JI, Chung YJ, Jeon YK, Yoon BH, Kim HY, Lee SH, Lee J, Hong S (2019) Position statement on the use of bone turnover markers for osteoporosis treatment. J Bone Metab 26:213\u2013224","journal-title":"J Bone Metab"},{"key":"6059_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","volume":"36","author":"N Okada","year":"2013","unstructured":"Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36:1622\u20131626","journal-title":"Biol Pharm Bull"},{"key":"6059_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1210\/endo.134.1.8275930","volume":"134","author":"JM Britto","year":"1994","unstructured":"Britto JM, Fenton AJ, Holloway WR, Nicholson GC (1994) Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134:169\u2013176","journal-title":"Endocrinology"},{"key":"6059_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/JCI108497","volume":"58","author":"GR Mundy","year":"1976","unstructured":"Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG (1976) Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58:529\u2013534","journal-title":"J Clin Invest"},{"key":"6059_CR18","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1172\/JCI122151","volume":"128","author":"S Khosla","year":"2018","unstructured":"Khosla S, Drake MT, Volkman TL, Thicke BS, Achenbach SJ, Atkinson EJ, Joyner MJ, Rosen CJ, Monroe DG, Farr JN (2018) Sympathetic beta1-adrenergic signaling contributes to regulation of human bone metabolism. J Clin Invest 128:4832\u20134842","journal-title":"J Clin Invest"},{"key":"6059_CR19","doi-asserted-by":"publisher","first-page":"bcr2014206967","DOI":"10.1136\/bcr-2014-206967","volume":"2015","author":"T Shin","year":"2015","unstructured":"Shin T (2015) Guerrero AF (2015) Calcium maelstrom: recalcitrant hypocalcaemia following rapid correction of thyrotoxicosis, exacerbated by pregnancy. BMJ Case Rep 2015:bcr2014206967","journal-title":"BMJ Case Rep"},{"key":"6059_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"AL Huynh","year":"2016","unstructured":"Huynh AL, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf 25:1274\u20131278","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06059-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T14:12:19Z","timestamp":1642083139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06059-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6059"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06059-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}